1️⃣ UCB just bought the autoimmune TCE race
UCB agreed on May 3 to acquire Candid Therapeutics for $2B upfront and up to $200M in milestones, adding cizutamig, a BCMAxCD3 T-cell engager already tested in autoimmune disease patients.
Why it matters
Autoimmune TCEs are moving from venture thesis to strategic balance sheets. UCB now has two B-cell-depleting bispecific bets after its Antengene deal, and the independent field just got narrower.
Coffee talk
If phase 1 immune-reset data is enough for $2B upfront, what does phase 2 need to show before everyone else gets priced out?
2️⃣ FDA gave PROTAC its first real label
FDA approved Arvinas and Pfizer’s Veppanu on May 1 for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy, with Guardant360 CDx cleared as the companion diagnostic.
Why it matters
This is the first FDA-approved PROTAC, but the label is narrow: median PFS was 5 months versus 2.1 months for fulvestrant in ESR1-mutated patients. Modality validation is not the same as commercial comfort.
Coffee talk
If the first PROTAC needs a new commercial partner on day one, how much of the platform premium survives launch reality?
3️⃣ CBER is back in acting-director mode
FDA named Katherine Szarama acting director of CBER after Vinay Prasad left the agency, putting vaccines, gene therapies and blood products under interim leadership again.
Why it matters
CBER has been where policy taste turns into review risk. Sponsors with biologics or advanced therapies now underwrite another period where the permanent decision-maker is still unknown.
Coffee talk
How many gene therapy timelines can tolerate one more FDA leadership handover?